Navigation Links
Takeda in Medical News

Healthcare Businesswomen's Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company

-- Event Marks 20th Anniversary of the HBA's Prestigious Industry Award -- FAIRFIELD, N.J., Feb. 17 /PRNewswire-USNewswire/ -- The Healthcare Businesswomen's Association (HBA) today announced that its 2009 "Woman of the Year" is Dr. Deborah Dunsire, President and Chief Executive Officer of M...

Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured

COLUMBIA, S.C., Feb. 11 /PRNewswire/ -- Welvista is pleased to announce it has reached an agreement with Takeda to dispense a selection of the company's medications to the uninsured through Welvista's no-cost prescription medication program. With the addition of six Takeda products, Welvista ...

Chemizon Announces Research Collaboration Expansion With Takeda

LONGMONT, Colo., Oct. 1 /PRNewswire/ -- Chemizon (010170, KOSDAQ) announced today that it has reached an agreement with Takeda Pharmaceutical Company Limited, to expand its current research collaboration focused on utilizing Chemizon's discovery platform. (Logo: http://www.newscom.com/cgi-bi...

Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab

Merck Pharmaceuticals from Germany and Takeda Pharmaceuticals from Japan to colloborate in marketing of Merck's cancer drug Matuzumab. Matuzumab is developed by Merck which is in its Phase II // clinical tiral. Takeda Pharmaceuticals will sign agreement with Merck to give royalty and sale be...

Sanofi-Aventis Recognized for Workplace Efforts to Prevent Cancer

...ceuticals, GHI, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, Millennium: The takeda Oncology Company, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute (NCI), Novartis, The Onco...

The State of Louisiana and Together Rx Access Join Forces to Improve Prescription Access for Uninsured Residents

...ologics, Inc.; Ortho Women's Health & Urology, a Division of Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc; PriCara, a Unit of Ortho-McNeil, Inc.; takeda Pharmaceuticals North America, Inc.; Tibotec Therapeutics, a Division of Centocor Ortho Biotech Products, L.P.; and Vistakon Pharmaceuticals, LLC. ...

Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29

...ncer. Motesanib is part of a broad co-development program between Amgen and takeda and Millennium: the takeda Oncology Company. AMG 423: The Company noted it exercised its opt...

Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research

.... Dr. Fu will be supported by a grant of $300K over 3 years to accomplish his research project. The LRF thanks Millennium Pharmaceuticals, Inc./The takeda Oncology Company for their generous support of this grant. "We are proud to be able to support lymphoma research through grants such as this one...

CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs

... gasoline and taxi, bus or train fare to and from their medical care. The program is funded in part by a generous grant from Millennium: The takeda Oncology Company. Cancer Care is a national non-profit organization based in New York City that provides free support services to people affected by ...

Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009

...elated to ongoing contractual payments from takeda associated with the conclusion of the TAP joint ve...-tax) and ongoing contractual payments from takeda associated with the conclusion of the TAP j...elated to ongoing contractual payments from takeda associated with the conclusion of the TAP j...
Takeda in Medical Technology

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer

THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination...

Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)

...ly 22, and OSAKA, Japan, July 23 /PRNewswire/ -- takeda Pharmaceutical Company Limited ("Takeda") today announced that takeda Global Research & Development Center, Inc., a ...n December 2007. On March 6, 2009 the FDA informed takeda that based on the December 2008 FDA Guidance title...

Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes

...6, and OSAKA, Japan, June 27, 2009 /PRNewswire/ -- takeda Pharmaceutical Company Limited ("Takeda") today announced that takeda Global Research & Development Center, Inc., a ...o diet and exercise. In recent months, the FDA and takeda have been in discussions about conducting an addit...

Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe

... OSAKA, Japan, June 3 /PRNewswire/ -- takeda Pharmaceutical Company Limited ("Takeda") announce.... With the results of this additional study, takeda expects that the MAA submissions will be made with...scovered by Takeda's wholly owned U.S. subsidiary, takeda San Diego, Inc. is a dipeptidyl peptidase IV (DPP-...

New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)

... EXTON, Pa., Feb. 24 /PRNewswire/ -- BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends(TM): Uloric (R) . takeda Pharmaceutical Company Limited announced that they received FDA approval for Uloric (R) (generic name: febuxostat) on February 13, 2009. Uloric (...

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial

...tCall/ -- Amgen (Nasdaq: AMGN ), Millennium: The takeda Oncology Company, and its parent company takeda Pharmaceutical Company Limited (TSE:4052) today an...rds of the study population. Amgen, Millennium and takeda plan to follow this recommendation which will requ...

Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease

...Disease OSAKA, Japan, Jan. 22 /PRNewswire/ -- takeda Pharmaceutical Company Limited ("Takeda") announce...ation of vedolizumab will be the responsibility of takeda Pharmaceuticals North America, Inc., a subsidiary of takeda Pharmaceutical Company Limited....

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The takeda Oncology Company today reported updated results ba...). About Millennium Millennium: The takeda Oncology Company, a leading biopharmaceutical comp.... Millennium Pharmaceuticals, Inc. was acquired by takeda Pharmaceutical Company Ltd. ("Takeda", TSE: 4502) ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The takeda Oncology Company today reported updated results fr.... About Millennium Millennium: The takeda Oncology Company, a leading biopharmaceutical comp.... Millennium Pharmaceuticals, Inc. was acquired by takeda Pharmaceutical Company Ltd. ("Takeda", TSE: 4502) ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The takeda Oncology Company today reported the Phase I result.... About Millennium Millennium: The takeda Oncology Company, a leading biopharmaceutical comp.... Millennium Pharmaceuticals, Inc. was acquired by takeda Pharmaceutical Company Ltd. ("Takeda", TSE: 4502) ...
Takeda in Biological News

New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers

...alled for contaminated culture to be discarded immediately. He and Folkman later developed TNP-470, a synthetic analog of fumagillin, with the help of takeda Chemical Industries in Japan (Nature, December 1990). It has shown activity against dozens of tumor types, though its mechanism of action is only part...
Takeda in Biological Technology

Takeda's Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO

SAN FRANCISCO, May 22 /PRNewswire/ -- Takeda San Francisco Inc. announced today the appointment of Mary Haak-Frendscho, Ph.D., as president and chief scientific officer. Dr. Haak-Frendscho will be responsible for leading all activities at Takeda San Francisco including overall research and pre...

Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia

PALO ALTO, Calif. and OSAKA, Japan, Oct. 17 /PRNewswire/ -- Affymax, Inc. (Nasdaq: AFFY ) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have been awarded the 2007 Deal of Distinction Award from the Licensing Executives Society of the U.S. and Canada (LES) for...

Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego

SAN DIEGO, Sept. 4 /PRNewswire/ -- Takeda San Diego announced today that Keith Wilson, Ph.D. has been named president and chief scientific officer (CSO). In this position, he is responsible for overseeing all activities related to Takeda San Diego, Takeda Pharmaceutical Company Limited's U.S.-...

Nanotech particles affect brain development in mice

...ice whose mothers were injected with the nanoparticles while pregnant showed alteration in gene expression related to neurological dysfunction. Ken takeda led a team of researchers from the Tokyo University of Science, Japan, who carried out the tests. He said, "Nanotechnology and the production of novel...

Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics

...gs. The 2006 Nobel Prize for medicine and physiology and a number of corporate acquisitions and investments by Novartis, Merck, AstraZeneca, Roche and takeda have injected billions of dollars into this novel technology and further fueled the enthusiasm for the great promise of siRNA therapeutic development....

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...fi-Aventis SA, Spectrum Pharmaceuticals, Inc., and takeda Pharmaceutical Company Limited. Market data and an...gh Terminates Collaboration with Novacea II-68 takeda Terminates JV Deal, Merges its Subsidiaries II-68 ... II-71 Cell Genesys Forms Global Alliance with takeda on GVAX Immunotherapy Development for Prostate...

Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer

...n from IDM Pharma, which was recently purchased by takeda Pharmaceuticals Limited, where he led the clinical...an served as vice president of clinical science at takeda Global Research & Development Center, Inc., a subsidiary of takeda Pharmaceutical Company Limited, where he was focus...

Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team

... of Proteolix's Board of Directors, was a clinical developer of the proteasome inhibitor VELCADE(R) at Millennium Pharmaceuticals (now a subsidiary of takeda Pharmaceutical Company). As CMO, he will be responsible for the advancement of carfilzomib, Proteolix's lead anti-cancer proteasome inhibitor for the...

Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development

...and consulted for a variety of biotech and pharmaceutical companies including GlaxoSmithKline, Karo Bio, Monsanto, Pfizer, Pharmacia, Searle, SPRL and takeda Pharmaceuticals. Professor Fletterick received his Ph.D. from Cornell University and did his postdoctoral research in molecular biophysics in the l...

FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout

...ore than 40 years, marking second FDA approval for takeda within one month DEERFIELD, Ill., and OSAKA, Japan, Feb. 13 /PRNewswire/ -- takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, takeda Pharmaceuticals North America, Inc., announced tod...
Other Tags
(Date:12/24/2014)... 24, 2014 The federal court ... the blood thinner caused life-threatening episodes of internal ... structure for the proceeding, Bernstein Liebhard LLP reports. ... Court plans to select lawyers to serve as ... on appointing a Plaintiffs’ Steering Committee, which will ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... which is used in the treatment of colon or ... also prescribed to patients who suffer from advanced gastrointestinal ... a multi-kinase inhibitor and it blocks many enzymes which ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter TUESDAY, ... have abstained from sex for one year will be allowed to ... that would reverse a 31-year ban on donations from men who ... announced Tuesday its intention to release a new draft guidance in ... from gay men. The FDA is changing its policy based ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- A new, injectable ... and Drug Administration. The agency on Tuesday approved ... those who are overweight and have at least one ... 2 diabetes or high cholesterol. Patients taking the ... low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Tara Haelle ... News) -- Teens are more likely to start smoking ... attention-deficit hyperactivity disorder (ADHD) or conduct disorder, new ... counsel families about the risk of substance use as ... Brinkman, research director at Cincinnati Pediatric Research Group, which ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading ... study that pinpoints fine-scale differences in genetic ancestry of ... . Since immigrants first arrived more than ... has served as a meeting place for ... history and the ongoing mixing of peoples with African, ...
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
Other Contents